Literature DB >> 28825493

Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery?

Peter W J Morrison1, Natalia N Porfiryeva2, Sukhmanpreet Chahal1, Ilgiz A Salakhov3, Charlène Lacourt4, Irina I Semina5, Rouslan I Moustafine2,5, Vitaliy V Khutoryanskiy1.   

Abstract

Crown ethers are cyclic molecules consisting of a ring containing several ether groups. The most common and important members of this series are 12-crown-4 (12C4), 15-crown-5 (15C5), and 18-crown-6 (18C6). These container molecules have the ability to sequester metal ions, and their complexes with drugs are able to traverse cell membranes. This study investigated 12C4, 15C5, and 18C6 for their ability to increase solubility of ocular drugs and enhance their penetration into the cornea. Phase solubility analysis determined crown ethers' ability to enhance the solubility of riboflavin, a drug used for the therapy of keratoconus, and these solutions were investigated for ocular drug permeation enhancing properties. Atomic absorption spectroscopy demonstrated crown ether solutions' ability to sequester Ca2+ from corneal epithelia, and crown ether mediated adsorption of riboflavin into the stroma was investigated. Induced corneal opacity studies assessed potential toxicity of crown ethers. Crown ethers enhanced riboflavin's aqueous solubility and its penetration into in vitro bovine corneas; the smaller sized crown ethers gave greatest enhancement. They were shown to sequester Ca2+ ions from corneal epithelia; doing so loosens cellular membrane tight junctions thus enhancing riboflavin penetration. Induced corneal opacity was similar to that afforded by benzalkonium chloride and less than is produced using polyaminocarboxylic acids. However, in vivo experiments performed in rats with 12C4 did not show any statistically significant permeability enhancement compared to enhancer-free formulation.

Entities:  

Keywords:  corneal epithelium; crown ethers; in vitro−in vivo correlation; ocular drug delivery; permeability enhancement; riboflavin; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28825493     DOI: 10.1021/acs.molpharmaceut.7b00556

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

2.  Polyaphron Formulations Stabilised with Different Water-Soluble Polymers for Ocular Drug Delivery.

Authors:  Roman V Moiseev; Fraser Steele; Vitaliy V Khutoryanskiy
Journal:  Pharmaceutics       Date:  2022-04-24       Impact factor: 6.525

Review 3.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

Review 4.  Integrating Stimuli-Responsive Properties in Host-Guest Supramolecular Drug Delivery Systems.

Authors:  Adam S Braegelman; Matthew J Webber
Journal:  Theranostics       Date:  2019-05-15       Impact factor: 11.556

5.  Thermodynamic and electrochemical study of tailor-made crown ethers for redox-switchable (pseudo)rotaxanes.

Authors:  Henrik Hupatz; Marius Gaedke; Hendrik V Schröder; Julia Beerhues; Arto Valkonen; Fabian Klautzsch; Sebastian Müller; Felix Witte; Kari Rissanen; Biprajit Sarkar; Christoph A Schalley
Journal:  Beilstein J Org Chem       Date:  2020-10-20       Impact factor: 2.883

6.  A p-tert-Tutyldihomooxacalix[4]arene Based Soft Gel for Sustained Drug Release in Water.

Authors:  Hao Guo; Runmiao Zhang; Ying Han; Jin Wang; Chaoguo Yan
Journal:  Front Chem       Date:  2020-02-28       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.